

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 117 570
A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 84200102.6

(51) Int. Cl.³: C 07 J 51/00, A 61 K 31/575


(22) Date of filing: 27.01.84

(30) Priority: 24.02.83 IT 1973783

(71) Applicant: ISTITUTO BIOLOGICO CHEMIOTERAPICO
"ABC" S.p.A., Via Crescentino 25, I-10154 Torino (IT)(43) Date of publication of application: 05.09.84
Bulletin 84/36(72) Inventor: DI Schiena, Michele Giuseppe, Via
Brunelleschi 30/c, Trezzano sul Naviglio Milano (IT)(84) Designated Contracting States: AT BE CH DE FR GB IT
LI LU NL SE(74) Representative: Giambrocono, Alfonso, Dr. Ing. et al,
Ing. A. Giambrocono & C. S.r.l. Via Rosolino Pilo 19/B,
I-20129 Milano (IT)

(54) Sodium salt of ursodeoxycholic sulphate.

(57) A new compound of the general formula I:



(I)

obtained from the ursodeoxycholic acid, soluble in water and its
pharmaceutical compositions.

EP 0 117 570 A1


- 1 -

Sodium salt of ursodeoxycholic sulphate

The present invention relates to the new sodium salt of ursodeoxycholic O-sulphate, hereinbelow called sodium ursosulphate.

The new compound of the invention has the following

5 general formula I:



10

15

20

Ursodeoxycholic acid and its use in therapy is already known in the literature (J. Biochem. Japan 7,505, (1927); Merck Index 9th Ed.). This compound is, in fact, a pharmaceutical agent effective in the qualitative and quantitative alterations of the biliary function, also including those having the bile saturated with cholesterol: in these cases ursodeoxycholic acid prevents the formation of cholesterol stones and it is also able to dissolve under suitable conditions the radiotransparent stones, if present.

Ursodeoxycholic acid is also used in the dispeptic painful

symptomatology from cholecistopatía with or without
calcolosis, in the biliary discinesies and connected
syndromes, in the lipemic alterations due to the increase
of cholesterol and/or triglycerides.

5 The daily dosage is 150-750 mg by oral route.

Both ursodeoxycholic acid and its sodium salt are
pratically insoluble in water. This characteristic
limits their therapeutic use to the solid formulations
only, such as capsules and tablets.

10 As it is well known, these formulations are not always
accepted by certain patients either for their
difficulty to be swallowed or for their gastric
intollerance.

Moreover capsules and tablets are not very suitable to
15 a flexible posology.

The new compound of the invention, sodium ursosulphate,
is characterized by the property of being very soluble
in water.

Also the free acid, ursodeoxycholic O-sulphate, is very
20 soluble in water: however, owing to its very high
acidity, it is preferably used in the form of a salt,
such as the new compound of the present invention.

Since the toxicity of sodium ursosulphate does not show
any significative differences and mantains the values
already known for ursodeoxycholic acid, this new

compound is successfully employed in the therapy of the clinic symptomatology wherein ursodeoxycholic acid is already used.

5 The more useful and advantageous pharmaceutical preparations for the administration of the new compound of the invention are all the liquid formulations, such as syrups (including extemporary forms), drops, monodose ampouls.

These liquid formulations allow to modify the posology of the new compound in accordance with the therapeutic case, the age of patients, the necessity to use an attack or maintenance therapy: it is possible, therefore, to perform the flexibility of the therapeutic dosage.

The new compound can be advantageously used also for preparing other oral pharmaceutical formulations, such as gelatine capsules, tablets (including gastro-resistant), emulsions, suspensions and granulates.

20 In addition to the high advantage of that solubility of the product of the invention, it has been surprisingly found that sodium ursosulphate (US) displays an activity in some cases higher than that of ursodeoxycholic acid (UA).

Pharmaco-toxicological trials, carried out on the product of the invention in comparison with UA, are following reported.

Action on the hyperdislipidemia caused by Triton WR-1339

in the rat

Albinus rats (Wistar) of 300-320 g each, having been fed only with water "ad libitum" for 12 hours, were treated with US and UA, by oral route, 4 hours before and 15 hours after the administration intraperitoneously of Triton WR-1339 at the dosage of 300 mg/kg in 10 ml/kg of physiologic solution at 0.9%.

US and UA dosages were 25, 50 and 100 mg/kg respectively and the rats were divided in the following groups of 10 animals each.

Group 1: Controls treated with 10 ml/kg of physiological solution at 0.9% orally.

Group 2: Controls treated with 300 mg/kg of Triton WR-1339 i.p. and 10 ml/kg of carboxy methyl cellulose (CMC) at 0.5%.

Group 3, 4 and 5: UA at 25, 50 and 100 mg/kg respectively suspended in 10 ml/kg of CMC at 0.5%.

Groups 6, 7 and 8: US at 25, 50 and 100 mg/kg respectively dissolved in 10 ml/kg of physiologic solution.

The following Tables 1 and 2 list the results of blood-tests from abdominal aorta of rats sacrificed 5 hours after the last treatment:

Table 1: US and UA action inhibiting the hyperlipidemia
from Triton WR-1339 in the rat.

Groups	Dose	Total cholesterol Average + SD mg/100ml serum	Inhibi- tion in compari- son with Group 2 in %	Triglycerids Average + SD mg/100ml serum	Inhibi- tion in compari- son with Group 2 in %	Total lipids Average + SD mg/100ml serum	Inhibi- tion in compari- son with Group 2 in %
1	-	66,4 ± 8,81	-	88,28 ± 17,06	-	442,28 ± 49,68	-
2	300mg/kg i.p.	296,0 ± 32,24	-	1312,28 ± 95,15	-	3818,4 ± 391,09	-
3	25mg/kg os	244,8 ± 34,5*	-15,9%	1167,14 ± 180,5*	-11,0%	3011,4 ± 513,6**	-21,1%
4	50mg/kg os	175,47 ± 54,26**	-40,7%	893,6 ± 298,1**	-31,9%	2517,3 ± 557,6**	-34,1%
5	100mg/kg os	155,2 ± 50,3**	-47,6%	628,8 ± 223,0**	-52,1%	2241,14 ± 517,4**	-41,3%
6	25mg/kg os	220,8 ± 36,4**	-25,4%	1040,6 ± 91,08**	-20,7%	2697,1 ± 706,8**	-29,4%
7	50mg/kg os	163,2 ± 25,7**	-44,3%	654,3 ± 206,5**	-50,1%	1972,6 ± 550,0**	-48,4%
8	100mg/kg os	147,2 ± 31,3**	-50,3%	583,4 ± 121,1**	-55,5%	1949,7 ± 273,9**	-48,9%

* P/0,05 ** P/0,001

0117570

Table 2: US and UA action inhibiting the hyperdislipidemia from Triton WR-1339 in the rat.


Groups	Dose	Alfa-Lipoproteins Average + SD mg/100 ml serum	Increase towards Group 2	Beta-Lipoproteins Average + SD mg/100 ml serum	Inhibition towards Group 2	Beta/alfa ratio Average + SD mg/100 ml serum	Inhibition towards Group 2
1	-	33,14 ± 4,12	-	33,25 ± 8,42	-	1,06 ± 0,38	-
2	300mg/kg i.p.	22,4 ± 3,3	-	273,6 ± 32,5	-	12,47 ± 2,64	-
3	25mg/kg os	27,6 ± 9,8*	+23,2%	221,17 ± 38,4*	-19,1%	8,95 ± 3,5*	-28,2%
4	50mg/kg os	41,7 ± 11,3**	+86,1%	133,7 ± 60,4**	-51,2%	3,88 ± 1,73**	-68,8%
5	100mg/kg os	39,64 ± 11,4**	+76,8%	115,5 ± 58,7**	-57,7%	3,41 ± 2,29**	-72,6%
6	25mg/kg os	29,2 ± 6,7*	+30,4%	191,5 ± 42,1**	-29,9%	7,23 ± 3,6**	-42,0%
7	50mg/kg os	39,32 ± 5,5**	+75,4%	123,8 ± 27,7**	-54,7%	3,15 ± 1,1**	-74,7%
8	100mg/kg os	44,8 ± 8,5**	+100%	102,3 ± 36,9**	-72,6%	2,46 ± 1,2**	-80,3%

* P/0,05 **P/0,001

From the above results it appears that the activity
inhibiting the hyperdislipidemia caused by Triton WR-1339
depends on the dosage both in US and in UA. Moreover,
it surprisingly appears that US is more active than UA in
5 all the considered tests owing to its complete solubility
which increases the adsorption and the bioavailability of
product.

Acute toxicity of sodium ursosulphate was tested in rats
by administering the different doses of the compound
10 directly in a physiologic solution at 0.9% in a volume
either of 10 ml/kg by oral route through a probe directly
to the stomach or of 5 ml/kg intraperitoneously or
intravenously.

The dosages administered to groups of 10 animals each
15 are reported in the following Tables 3 to 5 together with
the symptomatology observed for a period of 8 days.
In all the tests, the LD_{50} was not reached up to the
administered doses.



0117570

Table 3: Acute toxicity of US in the rat by oral administration

	Dose mg/kg	Died animals	Mortality %	Symptomatology
5	1000	0	0	N
	2000	0	0	N
	3000	0	0	D
	4000	0	0	D
	5000	2	20	D
10	6000	4	40	D

N = none

D = depression

Table 4: Acute toxicity of US in the rat by intraperitoneal administration

	Dose mg/kg	Died animals	Mortality %	Simptomatology
	500	0	0	N
	600	0	0	N
20	700	0	0	D
	800	0	0	D
	900	2	10	D

N = none

D = depression

Table 5: Acute toxicity of US in the rat by intravenous route

	Dose mg/kg	Died animals	Mortality	Symptomatology
5	400	0	0	N
	500	0	0	N
	600	0	0	D
	650	1	10	D + C
	700	1	10	D + C
10	750	2	20	D + C

N = none

D = depression

C = chronic convulsions

15 The preparation of the new compound of the invention is carried out according to the methods known in the art, such as by reacting ursodeoxycholic acid in anhydrous pyridine with gaseous sulphuric anhydride.

Object of the invention is, particularly, a vary effective
20 and simple method consisting of using the solid complex pyridine - sulphuric anhydride.

According to this method ursodeoxycholic acid is dissolved in N,N-dimethylformamide and then reacted with the solid complex pyridine - sulphuric anhydride in the ratio of

1.95 - 2.1 Mol (preferably 2 Mol) of this complex to 1 Mol of ursodeoxycholic acid.

The reaction temperature is from 0° to 100°C, preferably 20°-30°C.

5 After elimination of the dimethylformamide, for instance by distillation in vacuo, the new compound thus obtained in the acid form is treated with an aqueous, alcoholic or aqueous-alcoholic solution of sodium hydroxide to obtain the corresponding sodium ursosulphate. Preferred
10 alcohols are those wherein sodium hydroxide is soluble, such as methanol or ethanol. Other sodium compounds can be advantageously used, such as sodium bicarbonate, sodium carbonate or sodium-2-ethylhexanoate. Sodium ursosulphate is then separated, in the solid form,
15 by method commonly used, for instance crystallization, precipitation from solvents wherein the compound is insoluble, evaporation either in vacuo, or not, liophilization or spray-drying.

The following Examples illustrate but do not limit the invention.

20

EXAMPLE 1

3.92 g of ursodeoxycholic acid, dissolved in 50 ml of anhydrous dimethylformamide, were added with 3.20 g of the complex pyridine-sulphuric anhydride maintaining under stirring for 12 hours at 20°C.

N,N-dimethylformamide is evaporated off in vacuo and the oily residue, consisting of ursosulphate acid being very soluble in water with acid reaction, is reacted with 30 ml of 1 N sodium hydroxide.

5 After stirring, the aqueous solution is concentrated in vacuo to small volume and treated with 100 ml of methanol.

The turbid solution is filtered and the limpid filtrate is evaporated in vacuo to a small volume and added with 200 ml of acetone. The product crystallized under stirring, 10 it is separated by filtration and dried in the air. Yield 4.8 g. Sodium ursosulphate thus obtained is very soluble in water. The NMR analysis correspond to the chemical structure searched.

15 The conductimetric analysis (for the acid, sulphate and carboxylic groups) has the expected values.

H'-NMR analysis of the sample

Sodium ursosulphate in D₂O

0.71 (S) p.p.m. (in respect with TSP)	methyl linked to 21- position
1.00 (S) p.p.m. (in respect with TSP)	two methyl groups in 18- and 19- position
from 2.66 to 0.33 (S) " "	Addition of not well-identified multiplets
3.57 (S) p.p.m. (in respect with TSP)	Hydrogen atoms linked to C in 3- and 7- position

Conductimetric analysis

Sodium ursosulphate

$$R = \frac{SO_3^-}{COO^-} = 2.1$$

Example 2

Preparation of monodose ampouls

5 0.150 g of sodium ursosulphate are dissolved in 10 g of 70% sorbitol and 0.5 mg of black-current flavour.

The solution is used for preparing monodose ampouls.

Example 3

Preparation of syrups

10 1 g of sodium ursosulphate is dissolved in 36 g of sugar, 10 g of sorbitol, 0.0005 g of peppermint, g 0.1 of methyl p-oxybenzoate, 5 g of ethyl alcohol, water q.s. to 100 g. One spoon of syrup = 10 g = 0.10 g of sodium ursosulphate.

Example 4

15 Oral Drops

10 g of sodium ursosulphate are dissolved in 50 ml of 70% sorbitol, 0.180 g of methyl p-oxybenzoate and water q.s. to 100 g.

20 drops = 1 g = 0.10 g of sodium ursosulphate.

Example 5

20

Preparation of syrup

2 g of sodium ursosulphate are dissolved in 36 g of sugar, 0.0005 g of peppermint, 0.1 g of methyl p-oxybenzoate, 5 g of ethyl alcohol and water q.s. to 100 g.

One spoon of syrup = 10 g = 0.20 g of sodium ursosulphate.

Example 6

Oral Drops


40 g of sodium ursosulphate are dissolved in 50 ml of 70% sorbitol, 0.180 g of methyl p-oxybenzoate and water q.s.

5 to 100 g.

20 drops = 1 g = 0.40 g of sodium ursosulphate.

CLAIMS

1. Trisodium salt of ursodeoxycholic O-sulphate having the following general formula I:



10 2. A process for preparing the compound of the above general formula (I), characterized in that ursodesoxycholic acid, dissolved in dimethylformamide is reacted at a temperature ranging from 0° to 100°C, preferably 20°C, with the solid complex pyridine-sulphuric anhydride in a molar ratio ranging

15 from 1.95 to 2.1 Mol, preferably 2 Mol, the reaction mixture is allowed to stand for 12 hours, the solvent is evaporated off in vacuo, the resulting oily residue, consisting of ursodeoxycholic O-sulphate as free acid, is neutralized with a 1N aqueous, aqueous-alcoholic or alcoholic solution

20 of sodium hydroxide, and acetone is added to the filtered solution to crystallize the compound of the above formula I which is separated by filtration and dried in the air.

3. A pharmaceutical composition containing a suitable compound having the formula I reported in claim 1.



European Patent
Office

EUROPEAN SEARCH REPORT

0117570

Application number

EP 84 20 0102

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. ³)
A	STEROIDS, vol. 32, no. 1, July-August 1978, pages 73-88, Holdon Day, San Francisco, US J.F. PAGEAUX et al.: "Bile acid sulfates in serum bile acids determination" * Pages 76-77 *	1,2	C 07 J 51/00 A 61 K 31/575
A	--- CHEMICAL PHARMACEUTICAL BULLETIN, vol. 27, no. 6, June 1979, pages 1402-1411, Tokyo, JP JUNICHI GOTO et al.: "Synthesis of Monosulfates of unconjugated and conjugated bile acids" * Pages 1407,1409,1410 * -----	1,2..	TECHNICAL FIELDS SEARCHED (Int. Cl. ³) C 07 J 51/00 C 07 J 9/00
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 21-05-1984	Examiner HENRY J.C.
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			